Epilepsy affects about 0.5%-1% of the world population and is therefore one of the most common neurological disorders. In Germany about 600,000 people are affected, with 30,000 new cases appearing every year. Approximately 5% of the population experiences at least one seizure during their lifetime, without developing epilepsy. An epileptic seizure results from spontaneous, undesirable electrical activity of neurons in the brain, which can manifest as impaired consciousness, muscle twitch or tension, as well as complex actions. If epileptic seizures of this kind occur repeatedly and for no obvious reason, we talk about epilepsy. The possible causes of epileptic seizures can be as diverse as their clinical appearance. They can be divided into symptomatic epilepsies that are caused by tumors, malformations, ischemia or encephalitis, and genetically determined idiopathic epilepsies. This latter group, characterized by the lack of structural or other predisposing causes, often shows an age-dependency and can account for about 50% of all epilepsies. However, genetic modifications have also been found in focal forms of epilepsies, which only occur in one hemisphere (e.g. in symptomatic epilepsies at the site of lesions or tumors). Monogenic inheritance, with a single gene mutation causing the resulting phenotype, is rare. In the majority of cases, complex inheritance including many different genetic factors forms the basis of the epilepsy. The most common forms of idiopathic epilepsy showing a polygenic and complex inheritance are childhood and juvenile absence epilepsies (CAE, JAE), juvenile myoclonic epilepsy (JME) and epilepsy with grand mal seizures on awakening (EGMA). Early onset absence epilepsy (EOAE) and generalized/genetic epilepsy with febrile seizures plus (GEFS+) are also closely related to these forms. Genetic defects in epilepsies affect mostly ion channels, which are responsible for electrical transmission in the brain.
In the Department of Neurology and Epileptology at the University of Tübin-gen, we have been studying these genetic defects with the goal of finding specific disease-causing gene defects, understanding their molecular and cellular pathomechanisms and improving current and developing new therapeutic options. In recent years, we characterized several mutations in the SCN2A gene encoding the voltage-gated sodium channel Na V 1.2 [11, 12] , in the KCNQ2 gene encoding the voltage-gated K V 7.2 potassium channel ( [14] , reviewed in [15] ) as well as in the new epilepsy genes SLC2A1 (GLUT1, glucose transporter 1; [23] ) and PRRT2 encoding a presynaptic protein [20] . Together with cooperation partners in Europe, epilepsy patients in Germany and other European countries have been recruited and tested for epilepsy-causing genetic defects. Using novel technologies available for sequencing of the whole exome and genome enables rapid identification of genetic modifications. Thus genetic analysis of idiopathic epilepsies combined with functional studies can give rise to a better understanding of the disease, thereby avoiding unnecessary clinical diagnostics, enabling genetic and prognostic consulting and helping in the selection of possible therapy.
How ion channel defects can contribute to defective neuronal excitability
Most genetic defects found in idiopathic epilepsies affect ion channels, proteins located in the cell membrane that form selective pores for different ions (for a review see [10] ). The ion flux over the membrane is controlled by opening and closing the channels, so-called gating. Thus these channels define the electrical excitability of neurons in the brain. Genetic modifications of ion channels can affect their function and thereby alter the electrical impulse. This can further modify neuronal excitability, drive a neuronal network into synchronous activity and ultimately lead to an epileptic seizure. In the healthy brain ion channels within the membranes of excitatory and inhibitory neurons provide a neuronal balance (see . Fig. 1 ). Disruption of this balance due to ion channel defects can lead to epileptic seizures. This is further supported by the fact that most anticonvulsants used in clinical praxis affect different ion channels. Ion channels are protein pores permeable for specific ions in the intra-and extracellular space. Ionic transport is passive along an electrochemical gradient consisting of a chemical concentration gradient as well as the potential difference, the electrical driving force. The ion channels mainly studied in our group include voltage-gated Na + and K + channels as well as γ-aminobutyric acid-(GABA)-receptors, which initiate anion currents due to GABA binding. Voltage-gated ion channels define the resting membrane potential, provoke the development of action potentials and conduction along the axon and repolarize the membrane back to the resting membrane potential. Action potentials arriving on the presynaptic membrane lead to Ca 2+ influx and thus to the release of chemical messengers, the so-called neurotransmitters that provide information transmission between cells. In excitatory pyramidal cells the specific voltage-gated ion channels, such as Na V 1.2 and Na V 1.6 sodium channels [12] and K V 7.2 and K V 7.3 potassium channels [15] , are expressed in the axon initial segments (AIS), the origin of action potentials. In contrast, the Na V 1.1 sodium channel is found at the AIS of the inhibitory neurons [18] . Voltage-gated ion channels have three different conformational states, which can be changed by mutations in the channels: (1) closed, (2) open and (3) inactivated. A mutation in the ion channel protein can, for instance, lead to a shift in voltage-dependent activation and thereby change the ion flux at a specific membrane potential. Furthermore, excitatory and inhibitory neurons can be distinguished by the chemical second messengers used for conduction between cells: while excitatory neurons use glutamate or acetylcholine as neurotransmitters, inhibitory cells use mainly the second messenger γ-aminobutyric acid (GABA) (see . Fig. 1) . Mutations within the postsynaptic receptors of these messengers can disrupt conduction between cells and thus represent an epilepsy-causing defect. Below we summarize methodological strategies for the functional analysis of ion channel defects, and address major scientific findings contributing to our understanding of mechanisms of idiopathic epilepsies and the development of new therapeutic approaches.
Functional studies on ion channel defects
To study the effects of ion channel defects on the channel function, we use heterologous expression systems as well as neuronal and animal models. The first experimental step to study the molecular physiology of an ion channel and the effects of its genetic mutations is to express them in a system without endogenous channels with the same or similar function. Various mammalian cell lines and Xenopus laevis oocytes are most commonly used. The disadvantage of such systems is that the channels may behave differently compared to their natural environment. However, for many channels studied thus far very similar gating behaviour has been observed in both heterologous systems and natural tissue, supporting their use as a first line experimental approach. In order to confirm genetic data, screen channel defects affecting ion channel genes and study the involvement of impaired channel gating in the pathogenesis of epilepsy, we rely on heterologous expression as a relatively fast and efficient approach, enabling us to select a mutation for further complex studies in neural cellular and animal models (see . Fig. 2 ). In recent years we have studied many different mu- Defects in voltage-gated Na + and K + channels
Mutations in the SCN1A gene encoding the voltage-gated Na V 1.1 channel are the most common genetic defects in idiopathic epilepsy. They are associated with a broad spectrum of symptoms, ranging from severe early childhood encephalopathy (Dravet syndrome) to generalized/ genetic epilepsy with febrile seizures plus (GEFS+). Most patients with Dravet syndrome carry de novo mutations, which introduce an early stop codon in the SC-N1A gene, resulting in a truncated protein without function. Interestingly, the application of the sodium-channel blocker lamotrigine can aggravate the clinical situation in patients with Dravet syndrome. In addition, loss-of-function effects have also been described for non-truncating SCN1A mutations expressed in heterologous systems. A reduced function of voltage-gated sodium channels, which are responsible for the initiation and propagation of action potentials, should result in decreased membrane excitability. If this loss of function affects inhibitory neurons, it can result in hyperexcitability of neural networks and therefore induce epileptic seizures. Benign familial neonatal infantile seizures (BFNIS) occur in the first weeks to months of life and are caused by mutations in the SCN2A gene, encoding the sodium channel Na V 1.2 [1, 11, 12] . These mutations are so-called gain-of-function mutations predicting increased membrane excitability at the AIS, the source of action potentials (see . Fig. 3) .
Mutations in KCNQ2 and KCNQ3 genes encoding the voltage-gated potassium channels K V 7.2 and K V 7.3 have been associated with benign familial neonatal seizures (BFNS) disorder, characterized by seizures starting within the first days of life and remitting spontaneously after a few weeks or months. In some cases, a more severe phenotype has been reported, including the development of epileptic encephalopathy [24] . Furthermore, some mutations have been related to peripheral neuron hyperexcitability (PNH) or myokymia, with or without accompanying seizures (overview in [15] ). Pathophysiological studies in heterologous expression systems revealed that all KCNQ2 mutations cause a loss of the channel function. The molecular mechanisms of this loss of function include altered protein stability, impaired transport to the cell membrane or changes in channel gating [15] . A detailed characterization of a KCNQ2 mutation found in a Turkish family affected by a typical BFNS disorder is presented in . Fig. 4 [14] . K V 7.2 and K V 7.3 channels play a critical role in the regulation of the membrane potential at the subthreshold level of an action potential. Reduced activity of these channels slightly depolarizes the membrane potential in this range, which then results in faster and more frequent depolarization above the threshold level and increases neuronal excitability. A counteracting mechanism, based on the activation of K V 7 channels, shifts the membrane potential in the opposite direction and may be useful not only for the treatment of epilepsy, but also for other diseases characterized by increased neuronal excitability, such as migraine or neuropathic pain. The K V 7 channel opener retigabine has recently been introduced as a novel antiepileptic drug, confirming that these channels present a promising pharmacological target [19, 26] .
Defects in the ligand-gated ion channels: GABA A Receptors GABA A receptors present the most important inhibitory receptors in brain. Five different subunits belonging to eight different classes (α-ρ) and encoded by 17 different genes assemble into one GABA A receptor. The most abundant pentameric conformation in brain is made of two α1, two β2 and one γ2 subunits. Several different mutations associated with epilepsy have been reported to date [22] . The first mutations were found in the γ2 subunit families with CAE or GEFS+, and the majority of mutations detected so far affect this subunit. Furthermore, mutations have been reported in α1, α6 and δ6 subunits [5, 8] . All GABA A receptor mutations cause the expected loss-of-function effect in heterologous systems. For the α1-S326fs328X mutation we could for instance show that the loss of function is caused by impaired protein stability, such that the receptors harbouring the mutant subunit cannot be integrated into the cell membrane [13] .
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Where and when are different ion channels expressed?
Although the above-mentioned functional studies have largely contributed to our understanding of the disease, many questions remain unanswered. Physiological systems reflecting natural conditions are essential in order to better explore the functional mechanisms of the disease (see . Fig. 2) . Therefore, neurons of wildtype (WT) or genetically modified mouse strains are suitable. To study the function of ion channel defects in a neuronal background, mutated ion channels can be inserted into murine primary neuronal cultures using transfection, electroporation or viral infection. Functional studies of specifically inserted ion channels are nontrivial, since primary neurons are electrically excitable and thus express many endogenous ion channels (including the ones of interest). Thus, specific knock-out mice, where a certain gene is incapacitated and therefore a specific protein eliminated, are well suited to functional studies on specific ion channel defects. The expression of WT or mutant ion channels in primary knock-out cells can then be used to study the neural firing behaviour and impaired ionic currents of neurons with introduced ion channel defects, which can yield insights into the disease-causing mechanisms. In the past few years, in utero electroporation has been used more frequently to genetically manipulate specific neural precursor cells at different brain locations. Transfection of neural precursor cells of the brain area of interest is achieved by microinjection of plasmid DNA into the brain of embryonic mice within the uterus, followed by electrical stimulation. Using this method 70%-90% of newborn pups express the transfected plasmid. Coexpression with a fluorescent protein enables the study of the transfected cells even during development.
As already mentioned above, voltageand ligand-gated ion channels are localized in diverse subcellular compartments in different neurons (see also . Fig. 1) . To analyze the cellular localization of distinct ion channels in neurons and in different brain areas we applied immunohistochemical methods on primary neuronal cultures from murine embryonic hippocampi or murine brain slices. Many idiopathic epilepsy syndromes show a characteristic age dependence with the molecular mechanisms being unsettled. Using antibody stainings we could explore the age-dependent expression of different ion channels (see . Fig. 3 ) and show in mouse brain slices obtained at different developmental stages that the sodium channel Na V 1.2 is predominantly expressed in the AIS of hippocampal and cortical neurons at an early age and is later substituted by the voltage-gated ion channel Na V 1.6 [12] . This replacement in expression of the sodium channels can explain age-dependent seizures in BFNIS caused by mutations in the SCN2A gene.
Genetically modified mouse models advance our understanding of disease mechanisms
To study the effects of a mutation found in an epilepsy patient on the neuronal level and thus in physiological systems, genetically modified mouse models carrying human epilepsy-causing mutations have been used. With the help of a "humanized" mouse model we can study the disease mechanisms in single neurons, neuronal networks as well as in the living organism. Both transgenic and spontaneously mutant mice have proven to be an important tool for identifying novel molecular pathways for epilepsy, validating the causality of candidate genes isolated from epilepsy patients and their families, and for unraveling their pathogenic mechanisms and suggesting therapeutic options. In this way, unknown pathogenic mechanisms of ion channel defects in excitatory and inhibitory networks could be elucidated. As already mentioned above, different types of sodium channels are expressed in excitatory and inhibitory GABAergic neurons and play unequal roles in the excitability of cells. Knock-out and knock-in mouse models could show that iPS cells genetically modi ed mouse models Fig. 2 9 Heterologous expression systems, mouse models and induced pluripotent stem (iPS) cells to functionally study ion channel defects: methods used in our department to study causes of idiopathic epilepsies. Patients with idiopathic epilepsies are genetically analyzed and possible ion channel defects are functionally studied in heterologous expression systems. We also use mouse models or iPS cells of patients for characterization in a more physiological setting SCN1A deletions lead to reduced firing of inhibitory neurons and thus most likely to seizures in Dravet syndrome and GEFS+ patients [18, 27] . One of the first described GEFS+ mutations found in the SCN1A gene is R1648H in the voltage sensor of the Na V 1.1 channel [3] . Using a mouse model carrying this mutation [16] , we could show that inhibitory neurons in diverse brain regions exhibit a clear reduction in firing frequency [7] . Reduced inhibition in the cortex, thalamus and hippocampus most likely results in epileptic seizures in animals as well as in affected patients. Besides the defects in the α-subunit of the Na V 1.1 sodium channel, mutations in the SCN1B gene, encoding the β1-subunit of different Na + channels, have been associated with GEFS+. Heterozygous knock-in mice carrying the SCN1B-C121W mutation had increased core temperatures and showed a similar phenotype to the affected patients [25] . The WT β1-subunit is predominantly expressed in the AIS of 3 9 SCN2A mutations lead to increased channel activity. a A BFNIS mutation was introduced into the neonatal and adult splice variant of the Na V 1.2 channel and analyzed in tSA201 cells [12] . The mutation revealed a gain-offunction effect by impairing inactivation of this channel and increasing the so-called persistent current, which can depolarize the cell membrane and enhance neuronal excitability. Interestingly, this effect was only found in the neonatal splice variant, which could explain the age dependency of this disease. However, for other SCN2A mutations, a gain-of-function effect has been found in both neonatal and the adult splice variants, indicating that this may not be the general mechanism for transient seizure expression. b To understand the age-dependent occurrence of seizures in BFNIS we performed immunohistochemical analysis of cortical brain slices, obtained from mice at different ages, using specific antibodies against Na V 1.2 or Na V 1.6 (red), ankyrin-G (green) as the axon initial segment (AIS) marker and DA-PI (blue). In early stages of development Na V 1.2 is expressed at the AIS of cortical neurons, and is later replaced by Na V 1.6. Scale bar, 50 µm. (Modified from [12] ) pyramidal cells and is already missing to a large extent in heterozygous animals. It has been shown that the Na + channel β1-subunits modulate AIS excitability and that epilepsy can arise if this modulation is impaired. To study the disease mechanism in BFNIS, we are currently using a knockin mouse model. Initial experiments using a newly generated knock-in mouse with a SCN2A mutation (in cooperation with Dirk Isbrandt, Hamburg) confirmed the results of a clear "gain of function" found in heterologous expression systems. The Na V 1.2 channel defect leads to increased firing frequency of hippocampal pyramidal cells and thus to increased excitability in heterozygous animals [2] .
Although transgenic mouse models have led to important findings on idiopathic epilepsies, many problems persist. The variability of the course of disease within one family showing the same genetic defect is often high; therefore, the mechanisms behind this phenomenon are not well understood. Using different mouse models, it has been shown that the genetic background of the inbred mouse strains plays an important role in the epilepsy phenotypes as well as induced-seizure thresholds. This is why the contribution of specific ion channel defects to brain excitability is complex, even when they are associated with a clear Mendelian disease phenotype in mice or patients [6, 17] .
Induced pluripotent stem (iPS) cells
Although we have learned a great deal about ion channels and their function in the brain from the approaches described above, they do have several limitations: (1) the cell lines used for the in vitro studies are not neuron-like cells and therefore do not have properties of the cellular population primarily affected in epilepsy; (2) we can only study effects of a single mutation, making it difficult to explore and recognize polygenic pathomechanisms; and (3) studies on mouse models can be transferred to humans to only a certain degree, since both the physiological role of a specific protein as well as the compensatory mechanisms which may influence the ex- pression of the mutation may differ between the two systems. Thus, studies of the pathogenesis in human neuron-like cells from the same genetic background as the mutation would be an interesting option. Reprogramming of the skin fibroblasts obtained from patients into the induced pluripotent stem (iPS) cells may offer such a possibility. This reprogrammed cell population can be differentiated into glutamatergic and GABAergic neuronlike cells [9, 21] , which could be further characterized on a biochemical, morphological or electrophysiological level. Comparing the properties of the differentiated cells from patients carrying specific mutations to the ones obtained from unaffected individuals of the same age may offer better insight into the function of the affected protein and mechanisms of idiopathic epilepsies. Furthermore, such cells could be used for drug screening and enable the development of personalized therapy. We are currently establishing human models from idiopathic epilepsy patients with the hope of gaining a deeper understanding of the pathogenic mechanism of this disease.
